A recent collaborative study by researchers in the United States and South Korea found that a new compound composed of two drugs can prevent tumors from "breathing" and is expected to be used to treat various cancers in the future.
Researchers from the University of Texas at Austin and Korea's Korea University published a paper in a new issue of the journal American Chemistry. The new compound is mainly composed of the old chemotherapy drugs doxorubicin and dichloroacetate, and is fed with cancer. Two months after the mice, the tumor volume in the body was greatly reduced.
The researchers divided the cancer-bearing mice into three groups, one group fed a new compound for two months, one group fed doxorubicin for two months, and one group received no treatment. Previously, these cancer-bearing mice have developed some resistance to doxorubicin. The results showed that the tumors of mice taking the novel compounds were 50% smaller than those of the mice with doxorubicin alone, and 75% smaller than the tumors of the mice without drugs.
The researchers explained that the tumor used anaerobic metabolism in the early stage, when the chemotherapy drug works better. However, when the tumor matures, it will turn into aerobic metabolism, just as the running from the beginning of the "breathing difficulties" into the state, resulting in drug resistance. The addition of dichloroacetate in the new compound allows cancer cells to use anaerobic metabolism again and cannot “breathâ€, thus helping to improve chemotherapy.
The author of the paper, Jonathan Zessler, a professor at the University of Texas at Austin, said that the key to the new study is to combine the two active components into one molecule, ensuring that they simultaneously reach the tumor cells. (According to Xinhua News Agency, Washington, August 24th, reporter Zhou Zhou)
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com